Gilead's Trodelvy Surpasses Investors' Low Bar At ASCO, But Faces A Commercial Climb

The Phase III TROPICS-02 study in HR-positive/HER2-negative breast cancer was successful, but data for rival drug Enhertu overshadowed the results.

rock climbing
Gilead appears to have a tough climb for Trodelvy in HR+/HER2- breast cancer • Source: Shutterstock

Gilead Sciences, Inc. prepared investors to be underwhelmed by the Phase III data results from TROPICS-02, testing Trodelvy (sacituzumab govitecan-hziy) versus chemotherapy in heavily pre-treated HR-positive/HER2-negative metastatic breast cancer. So the data – presented at the American Society of Clinical Oncology (ASCO) annual meeting on 4 June – were about what investors were expecting or slightly better.

Nonetheless, impressive Phase III data at ASCO for a different antibody drug conjugate (ADC), AstraZeneca PLC/Daiichi Sankyo Co.,...

More from Anticancer

More from Therapeutic Category